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Mutational heterogeneity represents a significant barrier to development of therapies for many dominantly inherited
diseases. For example, 1100 mutations in the rhodopsin gene (RHO) have been identified in patients with retinitis
pigmentosa (RP). The development of therapies for dominant disorders that correct the primary genetic lesion and
overcome mutational heterogeneity is challenging. Hence, therapeutics comprising two elements—gene suppression in
conjunction with gene replacement—have been investigated. Suppression is targeted to a site independent of the mu-
tation; therefore, both mutant and wild-type alleles are suppressed. In parallel with suppression, a codon-modified re-
placement gene refractory to suppression is provided. Both in vitro and in vivo validation of suppression and replacement
for RHO-linked RP has been undertaken in the current study. RNA interference (RNAi) has been used to achieve ∼90%
in vivo suppression of RHO in photoreceptors, with use of adeno-associated virus (AAV) for delivery. Demonstration that
codon-modifed RHO genes express functional wild-type protein has been explored transgenically, together with in vivo
expression of AAV-delivered RHO-replacement genes in the presence of targeting RNAi molecules. Observation of potential
therapeutic benefit from AAV-delivered suppression and replacement therapies has been obtained in Pro23His mice.
Results provide the first in vivo indication that suppression and replacement can provide a therapeutic solution for
dominantly inherited disorders such as RHO-linked RP and can be employed to circumvent mutational heterogeneity.
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Elucidation of the molecular pathogenesis of inherited dis-
orders has highlighted the presence of substantial levels of
genetic heterogeneity (OMIM database). One of the most
genetically heterogeneous conditions defined to date is
retinitis pigmentosa (RP [MIM180380]), which involves
photoreceptor-cell degeneration and affects ∼1 in 3,000
people.1 More than 40 causative genes have been impli-
cated in RP (Retinal Information Network database). Al-
though it is timely to explore gene therapies for RP, inter-
and intragenic heterogeneity represent significant barriers
to therapeutic development. For example, 1100 mutations
in the human rhodopsin gene (RHO [GenBank accession
number NM_000539.2]), which encodes the photosensi-
tive pigment in rod photoreceptors, have been identified
in autosomal dominantly inherited RP (adRP). Notably,
the mutational heterogeneity in RHO-linked RP is mirrored
in many other dominantly inherited conditions (OMIM
database). Development of therapies for each individual
mutation would be technically difficult to achieve and
not economically viable; thus, a therapeutic approach that
circumvents mutational diversity would be of great value.
Elsewhere, we described a therapeutic strategy for domi-
nant genetic diseases, termed “mutation-independent
suppression and replacement.”2 This approach involves
suppression of both mutant and wild-type alleles of a gene
causative of a dominant disorder.2–4 Suppressors are de-
signed to be complementary in nucleotide sequence to a
site within a target transcript that is independent of the
disease-causing mutation(s). Since both mutant and wild-
type alleles are suppressed, suppression is undertaken in
conjunction with the provision of codon-modified re-
placement gene(s) refractory to suppression, thereby pro-
viding the wild-type protein. Such an approach overcomes
the need to design specific suppression agents targeting
each mutation in a given gene, which enables correction
of a genetic defect in a mutation-independent manner.
However, the approach involves two components—sup-
pression and replacement—and therefore is, in principle,
more complex than replacement-only therapies for reces-
sive disorders. For this reason, no in vivo demonstration
of the approach has been achieved to date.
Exploiting the degeneracy of the genetic code to facili-
tate therapeutic development has been suggested for dom-
inantly inherited conditions with the hallmark of muta-
tional heterogeneity.1–4 More specifically, in relation to
retinopathies, the approach has been proposed elsewhere
for RHO- and peripherin-linked adRP.2,3,5 Studies have been
undertaken, using ribozymes, that focused on the sup-
pression component of the approach.6 RNA interference
(RNAi)–mediated suppression with synthesized small in-
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Figure 1. RHO-suppression and -replacement constructs. A, Rep-
resentation of RHO suppressor-EGFP construct shBB-EGFP. (shQ1-
EGFP and shNT-EGFP have the same format.) shRNAs were expressed
from the H1 promoter and EGFP from the CMV immediate early
promoter. The SV40 polyadenylation signal was located at the 3′
end of the EGFP gene. B, Two-component suppression and replace-
ment construct shBB-rBB. (shQ1-rQ1 and shNT-rBB have the same
format.) Suppressors were expressed from the H1 promoter and
replacement RHO cDNAs from RhoP. Polyadenylation signals of the
RHO gene were included in the 1,829-bp fragment. For tissue cul-
ture and retinal explant experiments, these constructs were main-
tained in pEGFP-1 (A) or a CMV-promoterless derivative of pcDNA-
3.1 (B) and for in vivo experiments in the AAV vector. Restriction-
enzyme sites used for cloning are indicated. Promoters were sep-
arated by spacer-DNA fragments. Numbers indicate molecular sizes
(bp), and arrows indicate the direction of transcription. HGH in-
tphuman growth hormone intron.
terfering RNAs (siRNAs) or short hairpin RNAs (shRNAs)
in conjunction with codon-modified replacement genes
were explored for mouse rhodopsin7 and peripherin.8 Ad-
ditionally, mutation-specific suppression of RHO was at-
tempted, employing either ribozymes or RNAi.9,10 How-
ever, suppression targeted to specific mutation(s) limits
flexibility in suppressor design, thereby reducing the prob-
ability of identifying potent molecules.
In parallel with the design of therapeutic strategies for
dominant retinopathies, vectors for delivery of nucleotide-
based therapies to photoreceptors have been evaluated. In
this regard, a hybrid recombinant adeno-associated virus
(AAV) with serotype 2 inverted terminal repeats (ITRs) and
the serotype 5 capsid (AAV2/5) was shown to infect pho-
toreceptors preferentially in a variety of species, including
mouse, rat, dog, and macaque.11–14 Efficient transduction
of photoreceptors by AAV2/5, the safety profile of the vi-
rus in the CNS, and the proposed use of AAV2 in human
clinical trials15 have encouraged the exploration of AAV2/
5 for the therapeutic approach outlined in the current
study.
Key elements required for mutation-independent sup-
pression and replacement for dominantly inherited dis-
orders, with human RHO as an example, are presented in
the current study. RNAi has been employed as a means of
potent suppression of RHO expression, as evaluated in cell
culture, organotypic retinal explants, and in vivo, with
use of AAV-mediated delivery. Furthermore, the resistance
of transcripts from codon-modified replacement genes
to RNAi-mediated suppression, the generation of a trans-
genic mouse providing evidence of the functional equiv-
alence of RHO replacement genes, and potential benefits
of AAV-delivered therapies in mouse models of RP are pre-
sented. Results suggest that suppression and replacement
can provide a therapeutic solution for dominantly inher-
ited disorders such as adRP and can be employed to cir-
cumvent mutational heterogeneity.
Material and Methods
siRNA and shRNA
RHO-targeting siRNAs siB (target-position nucleotide [nt] 256–
277), siBB (nt 254–274), siC (nt 270–292), and siCC (nt 274–294)
were designed according to the method of Elbashir et al.16 siQ1
and siQ2, also targeting RHO (nt 650–670 and nt 671–694, re-
spectively), were designed using the HiPerformance siRNA de-
sign algorithm (Qiagen). siRNAs—an siRNA targeting enhanced
green fluorescent protein (EGFP [Entrez Gene accession number
U57608]), siEGFP (nt 256–277), and a nontargeting siRNA (siNT,
5′-UUCUCCGAACGUGUCACGU-3′)—were synthesized by Qia-
gen. siRNA target sequences differed by at least 4 nt from any
sequences in mouse and human databases (BLAST 2.2.617). siBB,
siQ1, and siNT were initially cloned downstream of the H1 pro-
moter, to generate shRNAs,18 and subsequently in pEGFP-1 (BD
Biosciences), to generate shBB-EGFP, shQ1-EGFP, and shNT-EGFP
(fig. 1A).
Replacement RHO Genes
Replacement (r) RHO cDNAs rBB, rCC, and rQ1, with degenerative
nucleotides altered at siBB, siCC, and siQ1 target sites, respec-
tively, were generated by primer-directed mutagenesis and were
cloned into pcDNA3.1 (Invitrogen). The cytomegalovirus (CMV)
promoter was replaced with either the human ubiquitin C pro-
moter (pUB6/V5-His [Invitrogen]) or a 1.7-kb fragment of the
mouse Rho promoter (RhoP). We thank Prof. W. Baehr, University
of Utah, for the original RHO cDNA construct. Altered nucleo-
tides, underlined in target sites of replacement genes, are as fol-
lows: rBB (5′-ATAAATTTTTTGACCCTGTAT-3′), rCC (5′-CTGTATG-
TGACGGTG-3′), and rQ1 (5′-TGTAGCTGCGGTATAGATTAT-3′).
Cell Culture, Mouse Retinal Explants,
and Fluorescence-Activated Cell Sorting (FACS)
CMV promoter–driven wild-type RHO or ubiquitin promoter–
driven replacement constructs rBB, rCC, or rQ1 and siRNAs, siB,
siBB, siC, siCC, siQ1, siQ2, siNT, or siEGFP were cotransfected
into HeLa cells (ATCC accession number CCL-2) as described in
the work of Millington-Ward et al.19 Twenty-four hours posttrans-
fection, RNA or cytoplasmic protein was isolated as described else-
where.8 Mouse retinal explants were prepared; were electropor-
ated with shBB-EGFP, shQ1-EGFP, or shNT-EGFP; and were main-
tained as described. Subsequently, retinas were trypsin dissoci-
ated, and retinal cells expressing EGFP were identified and sorted
by FACS.8
Real-Time RT-PCRs
RHO mRNA expression levels were assessed by real-time RT-PCR
on a 7300 Real Time PCR System (Applied Biosystems) with use
of a QuantiTect SYBR Green RT-PCR kit (Qiagen) and with b-actin
as an endogenous control, with RHO primers (forward, 5′-CTT-
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Figure 2. RHO suppression in HeLa cells. HeLa cells were transiently cotransfected three times in triplicate with wild-type RHO and
RHO-targeting siRNAs (siB, siBB, siC, siCC, siQ1, or siQ2) or control siRNAs (siEGFP or siNT). After transfection, RHO mRNA and protein
levels were evaluated by real-time RT-PCR (A), ELISA (A), and Alexa Fluor 568–labeled immunocytochemistry (B). Cell nuclei were
counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Error bars represent SD values.
TCCTGATCTGCTGGGTG-3′; reverse, 5′-GGCAAAGAACGCTGGG-
ATG-3′) and b-actin primers (forward, 5′-TCACCCACACTGTGCCC-
ATCTACGA-3′; reverse, 5′-CAGCGGAACCGCTCATTGCCAATGG-
3′). Typically, real-time RT-PCRs were performed twice in triplicate.
AAV
Recombinant AAV2/5 viruses were generated using a helper virus–
free system.20 Expression cassettes were cloned into pAAV-MCS
(Stratagene), between the inverted terminal repeats of AAV2. The
resulting constructs were transfected into human embryonic kid-
ney (HEK)–293 cells (ATCC [accession number CRL-1573]) with
pRep2/Cap521 and pHelper (Stratagene), at a ratio of 1:1:2. Fifty
150-mm plates of confluent cells were transfected (50 mg DNA
per plate) with polyethylenimine.22 Forty-eight hours posttrans-
fection, crude viral lysates were cleared23 and purified by CsCl2-
gradient centrifugation. AAV-containing fractions were dialyzed
against PBS. Genomic titres—that is, viral particles (vp/ml)—were
determined by quantitative real-time PCR.24 The generated AAVs
contained the shBB-EGFP and shNT-EGFP constructs (AAV-shBB-
EGFP and AAV-shNT-EGFP, respectively) (fig. 1A); RHO-suppres-
sion and -replacement constructs shBB-rBB, shQ1-rQ1, and shNT-
rBB (AAV-shBB-rBB, AAV-shQ1-rQ1, and AAV-shNT-rBB, respec-
tively) (fig. 1B); or a CMV promoter–driven EGFP gene (AAV-
EGFP).
Animals
Transgenic mice NHR/ Rho/, Pro23His/ Rho/, and RHO-
M/ Rho/ (see below) and Rho/ were used in this study.25
Rho/ mice have a severe degenerative retinopathy. The mice fail
to elaborate rod photoreceptor outer segments and show no rho-
dopsin immunostaining. At age 12 wk, the rod electroretinogram
(ERG) is not recordable, and the photoreceptor layer comprises
a single row of nuclei, probably representing cone cells.26 NHR
and Pro23His mice were first described by Olsson et al.27 NHR
mice on a Rho/ background express a human transgene and
display a wild-type phenotype.26 Histology of retinas from 10-d-
old Pro23His mice on a Rho/ background showed marked pho-
toreceptor degeneration. ERG analyses in 10-d-old mice showed
reduced a- and b-wave amplitudes. Only a single row of photo-
receptor cell nuclei remained in the outer nuclear layer (ONL). A
transgenic mouse model (RHO-M) was generated, which expresses
a replacement human RHO gene designed to avoid suppression
by short complementary oligonucleotides targeting a specific site
(codons 59–63) of the RHO mRNA. With use of PCR-directed mu-
tagenesis, the original sequence of CTCTACGTCACCGTC was
replaced by CTGTATGTGACGGTG (altered nucleotides under-
lined), both encoding the same amino acid sequence of LYVTV.
The replacement RHO gene was placed under the control of a
3.8-kb fragment of the mouse RhoP. Intron 9 of the HPRT gene
was cloned downstream of the RHO polyadenylation signal. The
construct was microinjected into male pronuclei of fertilized eggs,
to generate transgenic progeny. Four founder animals, identified
by Southern blotting, yielded four individual transgenic mouse
lines; one of these was evaluated in this study. All mice were
maintained under specific pathogen-free housing conditions.
Subretinal AAV Injection
Subretinal injections were performed in strict compliance with
the European Communities Regulations 2002 and 2005 (Cruelty
to Animals Act) and the Association for Research in Vision and
Ophthalmology statement for the use of animals in ophthalmic
and vision research. Mice were anesthetized by intraperitoneal
injection of medetomidine and ketamine (10 and 750 mg/10 g
body weight, respectively). Pupils were dilated with 1% cyclo-
pentolate and 2.5% phenylephrine, and, under local analgesia
(Amethocaine), a small puncture was made in the sclera. A 34-
gauge blunt-ended microneedle attached to a 10-ml syringe (Ham-
ilton) was inserted through the puncture, and 1–3 ml of 10 vp/
ml13–14 AAV in PBS was administered to the subretinal space, and
a retinal detachment was induced. Following subretinal injection,
a reversing agent (100 mg/10 g body weight [Atipamezole Hydro-
chloride]) was delivered by intraperitoneal injection. Body tem-
perature was maintained using a homeothermic heating device.
Newborn mice were prepared for subretinal injection with the
method described by Matsuda and Cepko.27
ELISA, Immunocytochemistry, and Microscopy
Rhodopsin ELISAs were performed in triplicate as described else-
where.8 The rhodopsin primary antibody, kindly provided by Prof.
R. S. Molday, University of British Colombia, Vancouver, was used
in a 1:500 dilution. Rhodopsin immunocytochemistry, fluores-
cent microscopy, epon embedding, and semithin sectioning were
performed as described elsewhere.7,28 ONL thickness was evalu-
ated in semithin resin-embedded sections, which were taken from
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Figure 3. Replacement RHO suppression in HeLa cells. Replace-
ment RHO sequences were generated with altered degenerate nu-
cleotides at siRNA target sites. HeLa cells were transiently co-
transfected three times in triplicate with a replacement RHO-ex-
pression vector (rBB, rCC, or rQ1) and a RHO-targeting siRNA (siBB,
siCC, or siQ1) or a nontargeting siRNA (siNT). Replacement RHO
mRNA levels were evaluated by real-time RT-PCR. Error bars rep-
resent SD values.
Figure 4. RHO suppression in retinal explants. Mouse retinas
( ), dissected from newborn NHR/ Rho/ pups, were elec-np 6
troporated with a construct coexpressing an shRNA targeting RHO
or a nontargeting shRNA and EGFP (shBB-EGFP, shQ1-EGFP, or shNT-
EGFP). Negative control explants were not electroporated. After 2
wk, organotypic cultures were dissociated with trypsin and were
analyzed by FACS. Red and blue dots represent gated and ungated
populations of dissociated explants, respectively. Scatterplots of
forward- (FSC) versus side-scatter (SSC) and histograms of EGFP
fluorescence of the gated population of nonelectroporated (A1 and
A2, EGFP-negative) and electroporated (A3 and A4, EGFP-positive)
retinas are given. The bar chart indicates RHO mRNA levels in
retinal explant cells expressing sNT-EGFP, sBB-EGFP, and sQ1-EGFP,
quantified by real-time RT-PCR. Error bars represent SD values.
the central meridian of the eye at 50-mm intervals. Approxi-
mately 40 measurements of ONL thickness per section from sup-
pression and replacement eyes and from control eyes were taken
using analysis 5.0 (Olympus Biosystems) on an HBO 100 Axioplan
2 microscope (Carl Zeiss). ONL measurements for treated and
control eyes were grouped and ordered by thickness, and, sub-
sequently, the highest and lowest 15% of values were analyzed.
RNase Protection Assay
RNA probes specific to Rho (5′-ACGGGCUCUUCGUAGACAGA-
GAC-3′), RHO (5′-GCGUACCACACCCGUCGCAUUGG-3′), or shBB
(5′-GUAGAGCGUGAGGAAGUUGAUG-3′) were obtained from
Sigma-Proligo. Probes and Decade size marker (Ambion) were 5′-
end labeled with P32-gATP (Amersham GE Healthcare) with use
of the mirVana Probe and Marker kit according to the manufac-
turer’s protocol (Ambion). RNase protection assays were per-
formed using the RPA III Ribonuclease Protection Assay kit and
the manufacturer’s protocol (Ambion). One picomole of labeled
probe was hybridized to 3 mg of mouse retinal RNA. Samples were
separated on 15% denaturing polyacrylamide gels.
ERG
Animals were dark adapted overnight and were prepared under
dim red light. Pupils were dilated with 1% cyclopentalate and
2.5% phenylephrine. Animals were anesthetized with ketamine
and xylazine (16 and 1.6 mg/10 g body weight, respectively) in-
jected intraperitoneally. Standardized flashes of light were pre-
sented to the mouse in a Ganzfeld bowl. ERG responses from
both eyes were recorded simultaneously by means of contact lens
electrodes (Medical Workshop), with use of 1% amethocaine as
topical anesthesia. Reference and ground electrodes were posi-
tioned subcutaneously, ∼1 mm from the temporal canthus and
anterior to the tail, respectively. Responses were analyzed using
a RetiScan RetiPort electrophysiology unit (Roland Consulting).
The protocol was based on that approved by the International
Clinical Standards Committee for human ERG. Rod-isolated re-
sponses were recorded using a dim white flash (25 dB maximal
intensity, where maximal flash intensity was 3 candelas/m2/s)
presented in the dark-adapted state. Maximal combined rod-cone
response to the maximal intensity flash was then recorded. After
a 10-min light adaptation to a background illumination of 30
candelas/m2, cone-isolated responses were recorded to the max-
imal intensity flash, presented initially as a single flash and sub-
sequently as 10-Hz flickers. a-Waves were measured from the base-
line to the trough and b-waves from the baseline (in the case of
rod-isolated responses) or from the a-wave to the trough.
Statistical Analysis
Data sets for a given construct were pooled and averaged, and
SD values were calculated. Statistical significance of differences
between control and target data sets were determined by either
Student’s two-tailed t test or analysis of variance (ANOVA) with
the least-significant-difference post hoc test (Data Desk 6.1 [Data
Descriptions]); differences with were considered statisti-P ! .05
cally significant.
Results
siRNA-Mediated Suppression and Replacement of Human
Rhodopsin in HeLa Cells
RNAi-mediated suppression of RHO was initially evalu-
ated in HeLa cells. siRNAs targeting RHO were cotrans-
fected with a CMV promoter–driven wild-type RHO. Trans-
fections were performed three times in quadruplicate.
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Figure 5. RHO suppression in photoreceptor cells in vivo. Adult transgenic NHR/ Rho/ mice were subretinally injected with 3 ml
of vp/ml AAV coexpressing a RHO-targeting or nontargeting shRNA and EGFP (AAV-shBB-EGFP or AAV-shNT-EGFP). Retinas were122# 10
analyzed 2 wk postinjection. Expression of the 21-nt shRNA BB, detected by RNase protection in two transduced retinas, is depicted
in lanes L1 and L2 (A). RHO RNA probes were labeled with P32-gATP, and protected RNA was separated on 15% denaturing acrylamide
gels (A). In lane M, size markers indicate 10, 20, and 30 nt. Bars represent RHO mRNA levels in FACS-sorted cells from dissociated
retinas ( ) transduced with either AAV-shBB-EGFP or AAV-shNT-EGFP (B). Suppression levels were determined by real-time RT-PCR.np 6
Error bars represent SD values. Rhodopsin immunocytochemistry (Cy3 labeled) and EGFP protein expression in cells from dissociated
retinas, transduced with either AAV-shBB-EGFP (arrows) or AAV-shNT-EGFP (arrow heads), are depicted (C). Cell nuclei were counterstained
with DAPI.
Real-time RT-PCRs, performed on RNAs extracted from
transfected cells 24 h posttransfection, demonstrated up
to 87% suppression ( ) (fig. 2A). siRNAs siBB, siCC,P ! .01
and siQ1 were selected for further analysis. Similar lev-
els of rhodopsin protein suppression were quantified by
ELISA (up to 88%; ) (fig. 2A) and were demonstratedP ! .01
by immunocytochemistry 24 h posttransfection (fig. 2B).
Subsequently, replacement RHO constructs rBB, rCC, and
rQ1 were generated, incorporating nucleotide changes at
degenerate positions over the target sites for siRNAs siBB,
siQ1, and siCC. Transfections were performed three times
in quadruplicate in HeLa cells. Replacement RHO con-
structs were not suppressed by corresponding siRNAs—for
example, rBB by siBB (fig. 3). However, significant levels
of suppression were obtained with other noncorrespond-
ing siRNAs—for example, siQ1 suppressed rBB and rCC
(fig. 3).
shRNA-Mediated Suppression of Human Rhodopsin
in Retinal Explants
To provide long-term RHO suppression, siBB and siQ1 were
cloned as shRNAs into an EGFP-expressing vector (shBB-
EGFP and shQ1-EGFP, respectively) (fig. 1A). Plasmids
were electroporated into retinal explants from newborn
NHR/ Rho/ mice. NHR/ mice express a wild-type hu-
man RHO gene and display a wild-type phenotype.25 Cells
from retinal explants ( ) were dissociated 2 wk pos-np 6
telectroporation, and EGFP-positive cells were isolated by
FACS (fig. 4A). Real-time RT-PCR was undertaken on RNA
extracted from EGFP-positive FACS-isolated cells, and re-
sults obtained in explants mirrored those found in HeLa
cells. RHO suppression of 185% was achieved ( )P ! .001
(fig. 4B).
AAV-shRNA–Mediated Suppression of Human RHO in Vivo
It is clear that long-term expression of therapies will be
required for a progressive retinopathy such as adRP. To
achieve long-term suppression in vivo, shBB-EGFP and the
nontargeting shNT-EGFP were engineered into AAV vec-
tors (AAV-shBB-EGFP and AAV-shNT-EGFP). The EGFP gene
enabled viral transduction to be monitored. Three micro-
liters of AAV-shBB-EGFP ( vp/ml) or AAV-shNT-122# 10
EGFP ( vp/ml) were subretinally injected into123# 10
adult NHR/ Rho/ mice. Two weeks postinjection, two
animals were sacrificed, and expression of the 21-nt shBB
was shown in two retinas with use of RNase protection
(fig. 5A). Retinas were dissociated, and EGFP-positive cells
were collected by FACS. RNAi-mediated suppression of
RHO, as evaluated by real-time RT-PCR 2 wk postinjection
( ), was ∼90% ( ) in AAV-shBB-EGFP–trans-np 6 P ! .001
duced photoreceptor cells (fig. 5B). Four retinas were dis-
sociated, and significant suppression of rhodopsin protein
expression was demonstrated in vivo in EGFP-positive
transduced cells by immunocytochemistry (fig. 5C).
Functional Rescue of Rho/ Mice with a Codon-Modified
RHO-Replacement Transgene
A transgenic mouse expressing a sequence-modified RHO
gene was generated (RHO-M). The 3.8-kb mouse rhodopsin
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Figure 6. Retinal histology and ERG analysis of RHO-M mouse.
Two-month-old Rho/ (wild type), Rho/, NHR/ Rho/, and
RHO-M/ Rho/ mice were analyzed by retinal histology and ERG
( ). A–C, Rhodopsin immunocytochemistry (Cy3) showing sim-np 8
ilar rod outer segment (ROS) labeling in Rho/, NHR/ Rho/,
and RHO-M/ Rho/ retinas, respectively. Nuclear layers were
stained with DAPI. INLpinner nuclear layer; GCLpganglion cell
layer. D, Representative rod-isolated ERG responses. Note that
there is natural variation in b-wave amplitude. The range with use
of our protocol in wild-type animals is 349–720 mv (mean 485)
and, in Rho/ animals, is 270–700 mv (mean 447).
Figure 7. Expression of replacement RHO in vivo. Ten-day-old
Rho/ mice were subretinally injected with a 1:1 mixture of 2 ml
of vp/ml of two AAV vectors: AAV-EGFP and AAV-shBB-122# 10
rBB. Rhodopsin, EGFP protein, and nuclei were detected by Cy3-
labeled immunocytochemistry, native fluorescence, and nuclear DAPI
staining, respectively. Low-magnification images show a cross sec-
tion of a whole injected eye, with arrowheads indicating the trans-
duced area (A and B). High-magnification laser-scanning micro-
graphs show transduced (C and D) and nontransduced (E and F)
areas. INLpinner nuclear layer; GCLpganglion cell layer; ROS-
prod outer segments.
promoter used to drive expression of the transgene was
also used to drive expression of EGFP in the plasmid p-
EGFP-1 (Rho-EGFP). A significant level of expression was
demonstrated by Rho-EGFP, and it was confined to pho-
toreceptor cells when newborn CD1 mouse retinal ex-
plants were electroporated with this construct (data not
shown). RHO-M/ Rho/ mice were evaluated at age 2
mo, for rescue of the retinal pathology present in Rho/
mice, by histology (fig. 6A–6C) and ERG (fig. 6D).
Rhodopsin immunolabeling in rod outer segments and
the thickness of ONLs were similar in wild-type Rho/ (fig.
6A), NHR/ Rho/ (fig. 6B) and RHO-M/ Rho/ (fig. 6C)
mice. Additionally, ERG responses were similar in wild-
type Rho/, Rho/, NHR/ Rho, /, and RHO-M/ Rho/
mice. ERG b-waves of rod-isolated responses of 500–700
mV were observed in mice of all genotypes (fig. 6D). The
amplitudes and timings of the combined rod and cone
responses to the maximal intensity flash presented in the
dark-adapted state, as well as the light-adapted cone-iso-
lated responses both to single flash and 10-Hz flickers,
were equivalent in all the genotypes examined (data not
shown). These results validate the use of the degeneracy
of the genetic code for engineering codon-modified hu-
man RHO genes that can provide functional human rho-
dopsin protein.
AAV-Delivered Suppression and Replacement of Human RHO
in Vivo
Since shBB and shQ1 were established as potent suppres-
sors and rBB and rQ1 as refractory to their corresponding
suppressors, shBB-rBB and shQ1-rQ1 were cloned into AAV
vectors, and viruses containing both elements of the ther-
apeutics were generated (AAV-shBB-rBB and AAV-shQ1-
rQ1). Three microliters of AAV-shBB-rBB was subretinally
injected into adult wild-type Rho/ mice ( ), andnp 12
replacement RHO mRNA expression was confirmed by RT-
PCR and RNase protection with RNA extracted 10 d post-
injection (data not shown). To demonstrate that AAV-de-
livered rBB is translated into protein, 2 ml of a 1:1 mix of
AAV-shBB-rBB and AAV-EGFP was subretinally injected
into 10-d-old Rho/ mice ( ). Two weeks postinjec-np 6
tion, rhodopsin and EGFP protein expression were deter-
mined using fluorescent microscopy. Marked rhodopsin
expression, overlapping with EGFP, was observed in trans-
duced areas (fig. 7).
Subsequently, 1 ml of AAV-shBB-rBB or AAV-shQ1-rQ1
was subretinally injected into newborn Pro23His/ Rho/
mice ( ) that presented with a retinal degenerationnp 10
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Figure 8. Histology of AAV-transduced Pro23His retinas. New-
born Pro23His/ Rho/ mice were subretinally injected with 1
ml of vp/ml AAV-shBB-rBB or AAV-EGFP ( ). Ten days122# 10 np 6
posttransduction, eyes were processed for semithin sectioning and
were stained with toluidine blue. Approximately 40 measurements
of ONL thickness (mm) in three layers per eye were taken. A, ONL
thickness (bars) of the central meridian of the eye, of the lowest
and highest 15% of values ( ). B and C, Representative im-P ! .01
ages of AAV-shBB-rBB– and AAV-EGFP (control)–injected sections
corresponding to highest ONL thickness values. Yellow arrows in-
dicate ONL thickness. INLpinner nuclear layer; GCLpganglion cell
layer. Error bars represent SD values.
resulting in complete loss of photoreceptors by age 2 wk.
In all animals, one eye was injected with therapeutic virus
(either AAV-shBB-rBB or AAV-shQ1-rQ1) and the other
with a control virus (AAV-EGFP). The early onset and rapid
nature of the retinopathy in young Pro23His pups pre-
cluded use of ERG as a readout for benefit. However, at
age 10 d, retinal histology was evaluated in semithin resin-
embedded sections cut at ∼50-mm intervals throughout
the central meridian of the eye ( ). From each sec-np 10
tion ∼40 measurements of ONL thickness were taken.
Since only a part of the retina is transduced by a single
subretinal injection of AAV (particularly in newborn pups),
to identify the transduced area, ONL measurements were
ordered by thickness, and the highest and lowest 15% of
values were grouped for analysis. Lowest values represent
thinnest ONL readings, most likely corresponding to pe-
ripheral areas of the retina and thus not in close proximity
to injection sites. Highest values represent thickest ONL
readings, most likely corresponding to central areas of the
retina and thus in closer proximity to injection sites. Sig-
nificant differences in ONL thickness between AAV-shBB-
rBB– and AAV-EGFP–treated eyes were observed. The ONL
of treated eyes was found to be ∼33% ( ) thickerP ! .001
than control-injected counterparts for the highest value
groupings (fig. 8A–8C). In the lowest value groupings, a
difference of ∼10% was observed (fig. 8A). These data pro-
vide evidence at the histological level that AAV2/5-de-
livered RNAi, in conjunction with provision of a codon-
modified replacement gene, can beneficially modulate the
retinopathy in Pro23His/ Rho/ mice.
Discussion
Central to the design of the study is the exploration of
therapies that overcome the significant mutational hetero-
geneity in dominant disorders such as RHO-linked adRP.
The degeneracy of the genetic code facilitates such an ap-
proach by enabling RNAi-mediated suppression in con-
junction with use of sequence-modified replacement genes
whose transcripts are RNAi resistant (fig. 3). Such an ap-
proach has been proposed but as yet not validated in vivo
for a number of other dominantly inherited conditions.
For example, Millington-Ward et al.19 have considered
suppression and replacement for type I collagen-linked
osteogenesis imperfecta type I (MIM #166200) in mesen-
chymal progenitor stem cells. Xia et al.29 proposed that
suppression and replacement represents a valuable ther-
apeutic strategy for copper zinc superoxide dimutase
(SOD1)–linked amyotrophic lateral sclerosis (MIM *147450)
and evaluated the approach in HEK-293 cells. Similarly,
Kim and Rossi4 described the use of suppression and re-
placement, employing expression of an EGFP-reporter
gene in vitro to demonstrate the principle. Additionally,
whereas RNAi-mediated suppression of mutant alleles has
been shown to provide therapeutic benefit for spinocer-
ebellar ataxia (MIM #183090)30 and Huntington disease
(MIM 143100),31 it still has to be established whether
therapies for these disorders will require inclusion of re-
placement genes. Suppression and replacement may also
prove necessary as a therapeutic strategy for such disor-
ders. More generally, elucidation of the molecular etiol-
ogies of genetic conditions over the past 2 decades has
served to highlight the enormous mutational heteroge-
neity in many disorders and hence the need for thera-
peutic strategies such as the suppression and replacement
presented in this work.
In the current study, substantial RNAi-based suppression
of human RHO has been achieved in HeLa cells (figs. 2
and 3), organotypic retinal explants (fig. 4), and in vivo
subsequent to subretinal injection of AAV vectors (fig. 5).
Observation of 188% RHO suppression in AAV-shRNA–
treated retinas represents the first demonstration of potent
suppression of a gene in photoreceptors after viral delivery
of shRNAs. In addition, the generation of a transgenic
mouse (RHO-M) expressing a codon-modified human RHO-
replacement gene has provided evidence in vivo of the
functionality of codon-modified replacement RHO genes.
Results obtained from both ERG and histology in RHO-
M/ Rho/ transgenic mice carrying this replacement
RHO gene were equivalent to those observed in wild-type
mice (Rho/), Rho / mice, and NHR/ Rho/ mice car-
rying a wild-type human RHO transgene (fig. 6).
An objective of the current study was in vivo demon-
stration of suppression and replacement. Hence, shRNAs
targeting RHO together with codon-modified RHO replace-
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ment genes have been engineered into AAV vectors. Ex-
pression of RNAi-resistant replacement genes in the pres-
ence of shRNAs was demonstrated in mice subretinally
injected with AAV vectors with use of real-time RT-PCR,
RNase protection assays, and immunocytochemistry (fig.
7). In addition, evidence suggesting therapeutic benefit
after administration of AAV vectors incorporating suppres-
sion and replacement components has been obtained in
Pro23His/ Rho/ mice expressing a mutant human RHO
allele and presenting with a rapid retinal degeneration.
Retinas from eyes injected with AAV-shBB-rBB or AAV-
shQ1-rQ1 showed preservation of the ONL when com-
pared with those injected with control virus—a 33% dif-
ference in ONL thickness was observed between treated
and control eyes in an animal model simulating human
RHO-linked RP (fig. 8).
Suppression and replacement, although providing sig-
nificant advantages in terms of condensing mutational
heterogeneity, is challenging, since the approach involves
2-nt–based components within a single therapeutic. En-
suring sufficient RNAi-mediated suppression in conjunc-
tion with appropriate levels of expression of the RNAi-
resistant replacement gene will clearly be important. How-
ever, in the current study, significant strides toward this
end were achieved—notably, ∼90% in vivo suppression of
RHO with use of AAV-delivered RNAi, demonstration that
a codon-modifed RHO gene expresses functional wild-type
protein, in vivo expression of AAV-delivered RHO re-
placement genes in the presence of targeting RNAi mol-
ecules, and observation of potential therapeutic benefit in
Pro23His mice. In summary, the study represents the first
in vivo indication that suppression and replacement as a
strategy can provide therapeutic benefit and can overcome
the mutational heterogeneity associated with RHO-linked
RP, a significant barrier to therapeutic development for
this and many other dominantly inherited genetic con-
ditions. Our results, in conjunction with accumulating
evidence that AAV represents a safe and efficient means
of delivering molecular therapies to photoreceptors,11 sug-
gest that AAV-delivered suppression and replacement may
well provide future therapies for patients with RHO-linked
RP, as well as for other disorders.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
ATCC, http://www.atcc.org/ (for HeLa cells [accession number
CCL-2]) and HEK-293 cells [accession number CRL-1573])
BLAST, http://www.ncbi.nlm.nih.gov/blast
Entrez Gene, http://www.ncbi.nlm.nih.gov/entrez/ (for EGFP [ac-
cession number U57608])
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for RHO [ac-
cession number NM_000539.2])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for RP, type I collagen-linked osteoge-
nesis imperfecta type I, SOD1-linked amyotrophic lateral scle-
rosis, spinocerebellar ataxia, and Huntington disease)
Retinal Information Network database, http://www.sph.uth.tmc
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